An Evaluation of Long-term Outcomes in Adults With Pediatric-Onset Morphea
Open Access
- 1 September 2010
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 146 (9) , 1044-1045
- https://doi.org/10.1001/archdermatol.2010.239
Abstract
The prevalence of morphea in childhood is not well established, but reports suggest that approximately two-thirds of linear morphea cases occur before age 18 years, and 20% to 30% of morphea cases overall begin in childhood.1,2 Studies have described substantial morbidity in children with morphea, but to our knowledge none has addressed the disease effects when the patients reach adulthood (age ≥18 years). To assess the impact of childhood morphea in adults, we searched the Morphea Registry and DNA Repository at the University of Texas Southwestern Medical Center (UTSW) for adults with pediatric-onset morphea (APOMs), and we report our findings herein.Keywords
This publication has 7 references indexed in Scilit:
- Distinct Autoimmune Syndromes in Morphea: A Review of 245 Adult and Pediatric CasesYearbook of Dermatology and Dermatologic Surgery, 2010
- Distinct Autoimmune Syndromes in MorpheaArchives of Dermatology, 2009
- Pediatric morphea (localized scleroderma): Review of 136 patientsJournal of the American Academy of Dermatology, 2008
- Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international studyRheumatology, 2005
- Morphea and localized scleroderma in childrenSeminars in Cutaneous Medicine and Surgery, 1999
- The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993.1997
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994